NASDAQ$LENZ
LENZ Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
LENZ Therapeutics reported Q2 2025 revenue of $5.0M, a net loss of $14.9M, diluted EPS of $-0.53.
For Q2 2025, LENZ Therapeutics reported Revenue was $5.0M, net loss was $14.9M, diluted EPS was $-0.53. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $5.0M for Q2 2025.
- Net loss $14.9M.
- Diluted EPS $-0.53.
Headline financials
Revenue & EPS history
LENZ Therapeutics Inc · Revenue · Quarterly
$5M
Forward guidance
Healthcare outlook emphasizes reimbursement, pipeline milestones, and path to profitability.
Tailwinds
- Product launches and partnership economics.
- Cost discipline and cash runway.
Headwinds
- Clinical, regulatory, and pricing risk.
- Operating losses until scale is reached.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q2 2025
-2.8%
Avg return
Earnings day
-3.7%
Avg return
5 days after
-5.1%
Avg return
30 days after
20%
2 / 10 earnings
Positive
+5.0%
Q2 2022
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +0.0% | -7.0% | — | |
| Q1 2026 | -0.8% | -27.1% | -34.5% | |
| Q3 2025 | -23.5% | -17.3% | -4.7% | |
| Q2 2025 | -2.9% | -7.4% | +22.0% | |
| Q3 2023 | -1.7% | -0.4% | -1.3% | |
| Q2 2023 | -4.5% | -4.5% | -17.4% | |
| Q1 2023 | -0.3% | -3.2% | -8.4% | |
| Q3 2022 | +1.9% | +7.1% | +1.9% | |
| Q2 2022 | +5.0% | +9.3% | -9.0% | |
| Q1 2022 | -0.9% | +13.9% | +5.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro